BTCC
/
BTCC Square
/
Global Cryptocurrency
/
HCW Biologics Stock Surges 55% on Promising Cancer Treatment Data
HCW Biologics Stock Surges 55% on Promising Cancer Treatment Data
18
2
BTCCSquare news:
HCW Biologics (HCWB) shares skyrocketed 54.16% in pre-market trading after unveiling breakthrough preclinical results for its second-generation pembrolizumab-based immunotherapy targeting pancreatic and ovarian cancers. The biopharma's proprietary TRBC platform demonstrated superior immune-cell activation and tumor infiltration compared to existing treatments.
Founder Dr. Hing Wong confirmed the data will be presented at Nova Southeastern University's Pharmacy Seminar Series on September 12, 2025, setting the stage for potential Phase I trial announcements. The rally marks one of the largest single-day moves for the clinical-stage company since its IPO.
By:
